Note 2 - Summary of Significant Accounting Policies (Tables)

9 Months Ended

Sep. 30, 2025

Notes Tables

Disaggregation of Revenue [Table Text Block]

	Three Months Ended September 30,						Nine Months Ended September 30,
Product Revenue by Sales Channel	2025			2024			2025			2024
Product Revenue
Direct-to-consumer	$	137		$	130		$	277		$	557
Reseller		24			16			48			110
Returns		(15	)		(20	)		(23	)		(67	)
Revenue	$	146		$	126		$	302		$	600

Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]

	Three Months Ended						Nine Months Ended
	September 30,						September 30,
	2025			2024			2025			2024
(In thousands, except per share amounts)
Net loss	$	(2,596	)	$	(1,431	)	$	(6,029	)	$	(4,178	)
Less dividends on Series B Preferred Stock		(36	)		—			(37	)		—
Deemed dividends on warrants		(10	)		—			(10	)		—
Net loss available to common stockholders		(2,642	)		(1,431	)		(6,076	)		(4,178	)
Weighted average number of shares of common stock outstanding		1,320,778			364,184			928,971			229,291
Net loss per share - basic	$	(2.00	)	$	(3.93	)	$	(6.54	)	$	(18.22	)

Series A and B Preferred Stock [Member]

Notes Tables

Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]

	Three Months Ended						Nine Months Ended
	September 30, 2025						September 30, 2025
	2025			2024			2025			2024
(In thousands, except per share amounts)
Net loss attributed to Tivic Health Systems, Inc.	$	(2,596	)	$	(1,431	)	$	(6,029	)	$	(4,178	)
Dividends on Series B Preferred Stock		(36	)		—			(37	)		—
Deemed dividends on warrants		(10	)		—			(10	)		—
Net loss attributed to Tivic Health Systems, Inc.		(2,642	)		(1,431	)		(6,076	)		(4,178	)
Basic and diluted weighted average number of shares outstanding		1,320,778			364,184			928,971			229,291
Net loss per share - basic and diluted	$	(2.00	)	$	(3.93	)	$	(6.54	)	$	(18.22	)